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Depression in Lung Cancer Patients: Role of Perceived Stigma
Brian D. Gonzalez
ABSTRACT
Previous research suggests that lung cancer patients are at an increased risk for
depressive symptomatology; however, little is known about the possible etiology or
correlates of depression among these patients. This study examined the relationship
between perceived stigma and depressive symptomatology among lung cancer patients,
and sought to find potential mediators of this relationship. It was hypothesized that more
perceived stigma would be related to greater depressive symptomatology and that
perceived stigma would contribute unique variance to depressive symptomatology above
and beyond that contributed by clinical, demographic, and psychosocial variables. A
sample of 95 participants receiving chemotherapy for stage II-IV non-small cell lung
cancer was recruited during routine outpatient chemotherapy visits. A medical chart
review was conducted to assess clinical factors and participants completed a standard
demographic questionnaire as well as measures of perceived stigma, depressive
symptomatology, and other psychosocial variables. As hypothesized, there was a positive
association of perceived stigma to depressive symptomatology. Perceived stigma
contributed significant unique variance to depressive symptomatology. In addition dyadic
adjustment and dysfunctional attitudes mediated this relationship. Future research should
aim to replicate and extend these findings in longitudinal analyses and attempt to
vi

ameliorate lung cancer patients’ depressive symptomatology by targeting perceived
stigma.
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Introduction
It is estimated that 215,020 people will be diagnosed with lung cancer in the
United States in 2009 (Jemal et al., 2008). While early-stage lung cancer patients can
sometimes be cured, many patients face bouts with lung cancer that can last several years
and during which they may receive surgery, chemotherapy, radiation therapy, or all three.
The effects of the illness and some of the side-effects of its treatment often make
concealing one’s illness from others difficult, leaving lung cancer patients vulnerable to
stigmatization. The potential contributory role of tobacco use to the development of lung
cancer is another factor that may contribute to perceived stigmatization. Patients with this
illness are at increased risk for depressive symptomatology, which itself is related to
poorer quality of life among cancer patients (Hyodo et al., 1999; Montazeri, Milroy,
Hole, McEwen, & Gillis, 1998; Turner, Muers, Haward, & Mulley, 2007; Visser &
Smets, 1998). Some correlates of depressive symptomatology in lung cancer patients
have been identified; however, the potential contribution of illness-related perceived
stigma has yet to be examined. To address this issue, the current study seeks to determine
whether perceived stigma is related to depressive symptomatology among lung cancer
patients.
Lung Cancer
Lung cancer is one of the most common and deadliest forms of cancer. It accounts
for 15% of new cancer cases and 29% of cancer deaths annually (Jemal et al., 2008). It is
the leading cause of cancer-related death in males (31%) and females (26%), far
1

outnumbering the rates of deaths due to prostate cancer (10%) and breast cancer (15%) in
males and females, respectively (Jemal et al., 2008). The discrepancy between the
prevalence of lung cancer and the percentage of cancer-related deaths attributed to lung
cancer is a testament to its lethality. This lethality is exacerbated by the late stage at
which lung cancer is often detected, which is partly due to the less-than-optimal detection
methods (e.g. chest x-rays); newer methods (e.g., spiral CT scans) remain controversial
(Kaneko et al., 1996). In addition, doctors may have difficulty differentiating symptoms
of lung cancer from similar smoking-related problems, which may be another factor
contributing to the late stage in which lung cancer is often detected. For example, in a
recent qualitative study, lung cancer patients reported that their disease-related symptoms
were often ignored by medical doctors, sometimes for several years, and attributed
instead to “smoker’s cough” (Chapple, Ziebland, & McPherson, 2004).
Depression in Lung Cancer Patients
Lung cancer patients often report experiencing symptoms such as fatigue,
insomnia, pain, and depression (Degner & Sloan, 1995; Sarna, 1993; Sarna, 1998).
Several studies of lung cancer patients have found high rates of clinically significant
depressive symptomatology shortly after diagnosis. For example, in a study of patients in
Japan who had recently received a lung cancer diagnosis, 31% exhibited clinically
significant levels of depressive symptomatology (Hyodo et al., 1999). Similarly, a study
of lung cancer patients in Scotland found that 23% endorsed clinically significant
depressive symptomatology when they were informed of their diagnosis (Montazeri et
al., 1998). Additionally, a study of lung cancer patients in Britain about to receive
radiotherapy found a 21% rate of clinically significant depressive symptomatology
2

(Turner et al., 2007). Hopwood and Stephens (2000) sampled lung cancer patients
recruited into palliative therapy medication trials throughout the United Kingdom and
reported a pre-treatment rate of clinically significant depressive symptomatology of 33%.
The highest reported rate of depressive symptomatology is 44%, reported in a study of
lung cancer patients referred to an Italian specialist center (Buccheri, 1998).
Some evidence suggests that depressive symptomatology in lung cancer patients
may remain elevated after treatment completion . For example, a postoperative study of
lung cancer patients who had smoked within months of surgery reported a 29% rate of
clinically significant depressive symptomatology (Walker, Zona, & Fisher, 2006).
Hopwood and Stephens (2000) reported that 29% of lung cancer patients assessed
between three and eight weeks after treatment had clinically significant depressive
symptomatology. Rates of depressive symptomatology were 34% and 44% in two studies
that assessed symptoms three months after the beginning of lung cancer treatment
(Montazeri et al., 1998; Nakaya et al., 2006). In addition, a study of elderly lung cancer
patients found that rates of clinically significant depressive symptomatology decreased
only slightly from 39% at one month after the beginning of treatment to 31% more than
one year later (Kurtz, Kurtz, Stommel, Given, & Given, 2002). The rates of depressive
symptomatology in lung cancer patients exceed those reported by individuals with other
types of cancer. For example, a sample of patients with breast cancer, head and neck
cancer, and lymphoma reported an 8% rate of elevated depressive symptomatology
(Berard, Boermeester, & Viljoen, 1998), and a sample of thyroid cancer patients reported
a 17% rate (Tagay et al., 2006).

3

Correlates of Depression in Lung Cancer Patients
Demographic Factors. Research on demographic correlates of depression in lung
cancer patients is limited and results are mixed. For example, two studies of lung cancer
patients have found women to be at higher risk of elevated depressive symptomatology
than men (Hopwood & Stephens, 2000; Hyodo et al., 1999), but three other studies found
no sex differences (Montazeri et al., 1998; Nakaya et al., 2006; Uchitomi et al., 2003).
Similarly, three studies reported that older lung cancer patients were more likely to
experience elevated depressive symptomatology compared to younger patients (Hyodo et
al., 1999; Walker, Zona, Larsen, & Fisher, 2004; Walker et al., 2006); however, three
other studies found no age differences (Montazeri et al., 1998; Nakaya et al., 2006;
Uchitomi et al., 2003). One study found that years of education was negatively related to
depressive symptomatology in lung cancer patients (Uchitomi et al., 2003); however, two
other studies found no relationship for education (Montazeri et al., 1998; Nakaya et al.,
2006). Neither income nor marital status has been found to be related to depressive
symptomatology among lung cancer patients (Montazeri et al., 1998; Nakaya et al., 2006;
Uchitomi et al., 2003). Although female gender, older age, and fewer years of education
may be positively related to depressive symptomatology in lung cancer patients, more
research is needed to clarify these relationships.
Clinical Factors. More definitive conclusions can be made about the
relationships between clinical factors and depressive symptomatology in lung cancer
patients, in part because there is more research in this area. Clinical factors studied
include performance status (i.e., clinical ratings of overall physical functioning), disease
stage, type of cancer treatment, functional impairment, and symptom severity. Studies
4

have consistently found that poorer performance status is related to greater depressive
symptomatology (Hopwood & Stephens, 2000; Hyodo et al., 1999; Nakaya et al., 2006;
Uchitomi et al., 2003; Walker et al., 2006). Several studies have reported no relationship
between disease stage and depressive symptomatology in lung cancer patients before
treatment (Montazeri et al., 1998; Nakaya et al., 2006) and as shortly as a few weeks and
as long as 12 months after treatment initiation (Montazeri et al., 1998; Uchitomi et al.,
2003; Walker et al., 2006). However, one study found that two weeks after the diagnosis
of lung cancer, patients with later disease stages exhibited less depressive
symptomatology than those with earlier disease stages (Hyodo et al., 1999). Only two
studies have examined whether depressive symptomatology varies as a function of lung
cancer treatment type. While Montazeri and colleagues (1998) found no relationship
between type of treatment and depressive symptomatology, Hyodo and colleagues (1999)
reported that patients who had not received radiotherapy were more depressed than
patients who had radiotherapy. Greater functional impairment (Hopwood & Stephens,
2000) and symptom severity (Hopwood & Stephens, 2000; Kurtz et al., 2002) have been
found to be positively related to greater depressive symptomatology; however, these
findings require further replication.
Psychosocial Factors. The psychosocial correlates of depressive symptomatology
in lung cancer patients have only recently begun to be studied. Less adaptive coping (i.e.,
less problem-focused coping) was found to be related to greater depressive
symptomatology in a sample of lung cancer patients who had recently undergone surgical
resection and had smoked within three months before surgery (Walker et al., 2006). In
addition, two aspects of greater social support have been found to be related to less
5

depressive symptomatology among lung cancer patients (Fisher Jr, La Greca, Greco,
Arfken, & Schneiderman, 1997). In separate studies of postoperative lung cancer
patients, nondirective emotional support (i.e., emotionally assisting or cooperating with
the patient while allowing the responsibility for behavior and choices to remain with the
patient) was associated with less depressive symptomatology, while directive
instrumental support (i.e., support that takes responsibility for financial and material
matters) was associated with more depressive symptomatology (Walker, Larsen, Zona,
Govindan, & Fisher, 2004; Walker et al., 2006). Thus, emerging evidence suggests that
coping and social support merit further study as psychosocial correlates of depressive
symptomatology in lung cancer patients.
Smoking Behavior. To date, only three studies have investigated the relationship
between smoking status and depressive symptomatology in lung cancer patients. One
study assessed smoking status before curative resection of non-small cell lung cancer
(NSCLC) and examined its relationship to depressive symptomatology one year later; no
relationship was evident (Uchitomi et al., 2003). In another study of NSCLC patients, no
relationship was found between preoperative smoking status and depressive
symptomatology assessed three months after surgery (Nakaya et al., 2006). In a third
study of patients who had smoked within the three months before lung cancer resection,
there was a trend towards a relationship between postoperative smoking status and
depressive symptomatology, such that those who continued smoking after surgery had
higher depressive symptomatology than those who had quit (Walker et al., 2004).
Although all three studies reported no significant relationship between depression and
smoking status, the evidence of such a relationship in the general population (Goodman
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& Capitman, 2000) and the potential implications it would carry if a similar relationship
were found among lung cancer patients argue for additional research on this topic.
Stigma in Lung Cancer Patients
An important factor that might be related to differences in depressive
symptomatology among lung cancer patients is perceived stigma. Modified Labeling
Theory, which was first used to describe the effects of stigma on individuals with
psychiatric disorders (Link, Cullen, Struening, Shrout, & Dohrenwend, 1989), posits that
once society labels an individual, they are subject to uniform responses from others.
These societal responses can constrain an individual into the role to which they are being
subjected, which can cause the individual to accept this role and incorporate it into their
identity. This process can often result in psychological harm. Perceived stigma, the
perception that one is subject to the uniform responses from others that are to be expected
for an individual with a certain label, has been studied in chronically-ill populations,
primarily with HIV-positive patients and those infected with Hepatitis C. Individuals with
these illnesses often perceive (accurately or inaccurately) that they are undergoing
uniform responses from society that are a result of their label (e.g., HIV positive). The
potential for stigma originates from the fact that these diseases are often transmitted via
unsafe sexual behavior and intravenous drug use (Beyrer et al., 2005; Purcell, Parsons,
Halkitis, Mizuno, & Woods, 2001).
Research has examined the relationship of perceived stigma to depressive
symptomatology in HIV positive individuals (Berger, Ferrans, & Lashley, 2001; Miles,
Burchinal, Holditch-Davis, Wasilewski, & Christian, 1997; Simbayi et al., 2007). One
such study sampled HIV positive individuals in South Africa and examined several
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potential demographic and psychosocial correlates (Simbayi et al., 2007). In addition to
finding a significant positive relationship between internalized stigma and depressive
symptomatology, this study also found that internalized stigma contributed unique
variance to depressive symptomatology over and above demographic factors (i.e., sex,
age, race, drugs and alcohol intake), clinical factors (i.e., taking HIV medications,
presence of HIV-related symptoms), and social support (Simbayi et al., 2007). Similar
findings were reported in a study of patients with the Hepatitis C virus visiting a clinic in
Iowa (Zickmund, Masuda, Ippolito, & LaBrecque, 2003). Findings indicated that a
majority of participants believed they had been stigmatized due to their illness and
consequently reported greater depressive symptomatology than those who did not
perceive stigmatization (Zickmund et al., 2003).
Similarly, lung cancer patients are likely to experience stigma as a function of
their disease because a particular behavior, smoking, is strongly associated with lung
cancer incidence. Smoking is estimated to cause about 90% of all lung cancer cases
(Godtfredsen, Prescott, & Osler, 2005). Because it is an often preventable disease,
patients and others may often blame the patient for their lung cancer diagnosis. To date,
research on perceived stigma in lung cancer patients is limited. One of the key pieces of
evidence is a qualitative study conducted by Chapple and colleagues (2004). In this
study, lung cancer patients in the United Kingdom were interviewed about their personal
history with the disease. A common theme reported by many patients involved feeling
stigmatized because of the strong association between smoking and lung cancer (Chapple
et al., 2004). Whereas patients suffering from other cancers (e.g., breast, prostate) may
not necessarily be blamed for their disease, these lung cancer patients reported feeling
8

blamed for their disease by friends, loved ones, and even healthcare professionals
(Chapple et al., 2004). Moreover, even patients who reported no history of smoking or
had stopped smoking several years before their diagnosis reported that they felt blamed
for their illness (Chapple et al., 2004). Perceived stigma may be related to depressive
symptomatology in lung cancer patients, as is the case for patients with Hepatitis C
((Zickmund et al., 2003) and HIV (Berger et al., 2001; Miles et al., 1997; Simbayi et al.,
2007); however, a search of the published literature suggests that this hypothesis has yet
to be tested.
Dyadic Adjustment and Dysfunctional Attitudes
In studying the relationship of stigma to depressive symptomatology in lung
cancer patients, it will be important to determine whether stigma accounts for variability
in depression distinct from other psychosocial variables often found to be associated with
depression. Dyadic adjustment (a measure of relational satisfaction) and dysfunctional
attitudes (a measure of cognitive vulnerability to depression) may be related to depressive
symptomatology in lung cancer patients, but these relationships have yet to be studied.
However, an association between poorer dyadic adjustment and greater depressive
symptomatology has been shown in studies of healthy populations (Herr, Hammen, &
Brennan, 2007; Jenewein et al., 2008; King & Arnett, 2005; Lewis, Fletcher, Cochrane,
& Fann, 2008; Whisman, 2007) as well as in medically-ill populations (Brotto et al.,
2008; King & Arnett, 2005). For example, a study of outpatient multiple sclerosis
patients and their significant others reported a relationship between poorer dyadic
adjustment and greater depressive symptomatology (King & Arnett, 2005). In addition, a
trial of a psycho-educational intervention aimed to reduce Female Sexual Arousal
9

Disorder symptoms in gynecologic cancer patients reported a relationship between poorer
dyadic adjustment and greater depressive symptomatology (Brotto et al., 2008).
Similarly, there is evidence for a relationship of dysfunctional attitudes to
depressive symptomatology in other populations. In a study of women with and without a
history of depression, more dysfunctional attitudes were associated with a greater number
of previous episodes of depression and greater likelihood to have a future depressive
episode (Otto et al., 2007). Also, in a sample of college undergraduates with and without
a history of depression, more dysfunctional attitudes were found to be related to greater
depressive symptomatology (Haffel et al., 2005). The relationships between dyadic
adjustment, dysfunctional attitudes, and depressive symptomatology merit exploration in
lung cancer patient populations.
Aims
The primary aim of this study was to examine the relationship between stigma, as
measured by the Social Impact Scale (SIS; Fife & Wright, 2000), and depressive
symptomatology, as measured by the Center for Epidemiological Studies Depression
Scale (CES-D; Radloff, 1977), in people with lung cancer. The study also aimed to
examine relationships between several psychosocial factors found to be related to
depression in other populations (i.e., coping, social support, dyadic adjustment, and
dysfunctional attitudes) and depressive symptomatology in lung cancer patients.
Additionally, this study aimed to determine which demographic and clinical factors are
related to perceived stigma. Finally, this study also sought to determine if stigma
accounts for variability in depressive symptomatology in lung cancer patients above and
beyond psychosocial factors found to be related to depressive symptomatology in other
10

populations, and if psychosocial factors mediate the relationship between perceived
stigma and depressive symptomatology.
Hypotheses
1. It was hypothesized that greater perceived stigma would be related to greater
depressive symptomatology.
2. Also, it was hypothesized that more avoidant coping, poorer social support,
poorer dyadic adjustment, and more dysfunctional attitudes would be related to
greater depressive symptomatology.
3. In addition, it was hypothesized that perceived stigma would explain unique
variance in depression over and above that explained by other psychosocial,
demographic, and clinical variables related to depressive symptomatology.
4. Finally, further analyses were conducted, based on the result of hypothesis testing,
to determine if psychosocial factors mediated the relationship between perceived
stigma and depressive symptomatology.
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Method
Participants
Eligibility criteria for the current study were: 1) receiving chemotherapy for stage
II, III, or IV non-small cell lung cancer 2) ≥ 18 years of age, 3) able to understand, speak,
and read English, 4) no history of other cancers with the exception of non-melanoma skin
cancer, 5) and able to provide informed consent.
Procedure
Study eligibility was determined via consultation with H. Lee Moffitt Cancer
Center Thoracic Oncology Program team members. Potential participants were
approached during a routine outpatient visit and had the study protocol explained. Those
eligible and interested provided written informed consent. Participants were given the
option of filling out the study measures during their outpatient visit or taking them home
and returning the completed measures in a self-addressed stamped envelope that was
provided. Participants were not compensated for their study participation.
Measures
Demographics and Background Information. Demographics and background
information were collected using a standardized self-report form. The variables assessed
were: age, sex, race, ethnicity, education, income, marital status, and employment status.
In addition, participants’ current and past smoking status, number of cigarettes smoked
per day, and years of smoking were assessed.
Clinical Information. The following clinical information was assessed via a
review of patients’ medical records: date of lung cancer diagnosis, disease stage, previous
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lung cancer treatment, planned lung cancer treatment, and ECOG performance status
(Oken et al., 1982).
Stigma. Experienced stigma was assessed using the Social Impact Scale (SIS;
Fife & Wright, 2000), a 24-item Likert-type scale which measures the extent to which
individuals with an illness believe they are experiencing social rejection, financial
insecurity, internalized shame, and social isolation as a result of their illness. In addition
to a total score, the measure yields subscale scores for the four aspects of experienced
stigma described above. These four subscales have been shown to have strong internal
consistency reliability (α range: .85 - .90), and though they are related, their relatively
low zero-order correlations with one another (r range: .28 – .66) suggest that they assess
divergent aspects of one’s illness-related stigma (Fife & Wright, 2000). In the current
study, analyses focused on the total score.
Dyadic Adjustment. Among participants who were living with a spouse or
partner, relational adjustment was assessed using the Dyadic Adjustment Scale-4 (DAS4; Sabourin, Valois, & Lussier, 2005), a Likert-type instrument designed for use with
married, unmarried, and same-sex cohabitating couples. It is comprised of 4 items: “How
often do you discuss or have you discussed divorce, separation, or terminating your
relationship?”; “In general, how often do you think that things between you and your
partner are going well?”; “Do you confide in your mate?”; and “Please circle the choice
which best describes the degree of happiness, all things considered, of your relationship.”
The DAS-4 has been shown to have adequate convergent and divergent validity, and a
cut-off score of 13 has been posited as optimal for distinguishing between individuals
with dyadic distress and those without (Sabourin et al., 2005).
13

Coping. Coping strategies were assessed using the Coping Responses Inventory
(CRI; Moos, 1993), a 48-item Likert-type instrument which assesses specific coping
responses via eight subscales. Four subscales assess approach coping styles; two are
considered behavioral approach coping styles (seeking guidance and support, problem
solving), and two are considered cognitive approach coping styles (logical analysis,
positive reappraisal) (Moos, 1993). Four subscales assess avoidant coping styles; two are
considered behavioral avoidant coping styles (seeking alternative rewards, emotional
discharge), and two are considered cognitive avoidant coping styles (cognitive avoidance,
acceptance or resignation) (Moos, 1993). The approach and avoidant scales of the CRI
have been shown to have adequate internal consistency reliability (α’s = .74 and .66,
respectively) in a sample of breast cancer patients (Hack & Degner, 2004). The eight
individual subscales of the CRI have been validated (Moos, 1993) and been shown to
have adequate internal consistency reliability (α range: .61 - .74) in a sample of ovarian
cancer patients (Chan, Ng, Lee, Ngan, & Wong, 2003). In the present study, analyses
focused on the cognitive avoidance subscale.
Social Support. Social support was assessed using the ENRICHD Social Support
Instrument (ESSI; Mitchell et al., 2003), a 5-item Likert-type instrument designed to
assess emotional support. The ESSI has been shown to have strong internal consistency
reliability (α = .87), good convergent validity with another measure of social support (r =
.62), and relatively weak correlations with measures of structural and tangible support (r
range: .20 - .25), which is indicative of divergent validity between emotional and other
types of social support (Mitchell et al., 2003). Sample questions include “Is there
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someone available to give you good advice about a problem?” and “Is there someone
available to you who shows you love and affection?” (Mitchell et al., 2003).
Dysfunctional Attitudes. Dysfunctional attitudes were assessed via the
Dysfunctional Attitudes Scale (DAS; Weissman & Beck, 1978), a 40-item Likert-type
self-report measure of cognitive distortions. Participants will report, on a 1 to 7 scale, the
degree to which they agree or disagree with items such as, “If a person asks for help, it is
a sign of weakness.” In addition to face validity, the DAS has demonstrated concurrent
validity with a measure of depressive symptomatology, including the ability to
distinguish between depressed and non-depressed individuals. The DAS also has good
internal consistency reliability (α range: .84 - .92) and test-retest reliability (r range: .80 –
.84; Weissman & Beck, 1978).
Depressive Symptomatology. Participants’ depressive symptomatology was
assessed using the Center for Epidemiological Studies Depression Scale (CES-D;
Radloff, 1977), a 20-item Likert-type self-report measure of depressive symptomatology.
Participants answered questions about how they felt over the past week. Sample
questions include, “I had trouble keeping my mind on what I was doing” and “I had
crying spells.” Because it is brief and its queries focus primarily on cognitive and
affective symptoms of depression rather than somatic symptoms, it is well-suited for use
with the medically-ill, such as lung cancer patients (Hann, Winter, & Jacobsen, 1999).
The CES-D has been shown to be a valid measure of depressive symptomatology with
excellent internal consistency reliability, as well as adequate test-retest reliability in a
sample of cancer patients (Hann et al., 1999).
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History of Depression. Participants’ history of Major Depressive Disorder
(MDD) prior to their lung cancer diagnosis was assessed using the Structured Clinical
Interview for DSM-IV (SCID; Gibbon & Williams, 2002). The SCID is a widely-used
structured interview which is used to determine diagnoses of numerous mental disorders
according to Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV;
(American Psychiatric Association, 2000) criteria. Good inter-rater agreement on
diagnoses of MDD (κ = .80; Zanarini et al., 2000) has been demonstrated using trained
raters. The mood episodes section of the SCID was administered by trained and
periodically-observed staff to assess lifetime history of MDD prior to the participant’s
date of diagnosis of lung cancer.
Statistical Analyses
To test the study hypotheses, correlational analyses were conducted to determine
the relationships between depressive symptomatology and each of the following:
perceived stigma, social support, avoidant coping responses, and dysfunctional attitudes.
A correlational analysis was also conducted to determine the relationship between
depressive symptomatology and dyadic adjustment among the subset of participants who
were living with a spouse or partner and were thus able to complete the measure
assessing dyadic adjustment.
In addition, independent samples t-tests, ANOVAs, and chi-square tests were
performed, as appropriate, to examine relationships between demographic and clinical
variables and depressive symptomatology.
Two hierarchical regression analyses were conducted to determine whether
perceived stigma accounts for unique variance in depressive symptomatology not
16

accounted for by other psychosocial variables and by demographic, clinical, and smoking
variables related to depressive symptomatology. In the first hierarchical regression
analysis, depressive symptomatology was the dependent variable, and independent
variables were included in the model in the following 4 steps:
1. Presence of a lifetime (before lung cancer diagnosis) history of depression
2. Any demographic, clinical, or smoking variable related to depressive
symptomatology
3. Social support, coping responses, and dysfunctional thoughts, regardless of
the significance of their relationship to depressive symptomatology
4. Perceived stigma
In the second hierarchical regression analysis, dyadic adjustment was added as an
independent variable in step 3. This analysis was conducted with the subset of
participants who were living with a spouse or partner and were able to complete the
DAS-4.
Four additional hierarchical regression analyses were conducted to determine
which components of perceived stigma contributed unique variance to depressive
symptomatology. In these analyses, the four subscales of the Social Impact Scale were
added as the independent variable in step 4.
In addition, independent samples t-tests, ANOVAs, and chi-square tests were
performed, as appropriate, to examine relationships between demographic and clinical
variables and perceived stigma.
Finally, mediational analyses were conducted to determine whether social
support, dyadic adjustment, coping styles, or dysfunctional attitudes mediated the
17

relationship between perceived stigma and depressive symptomatology. These analyses
followed the established protocol for determining mediation (MacKinnon, Fairchild, &
Fritz, 2007). MacKinnon, et al. (2007) lay out the following steps (see Figure 1):
1. The dependent variable (depressive symptomatology) is regressed on the
predictor (perceived stigma). The regression coefficient for the independent
variable (IV) in this equation is termed c.
2. The proposed mediator (psychosocial factor) is regressed on the predictor.
The regression coefficient for the IV in this equation is termed a.
3. The dependent variable is regressed on the predictor and mediator. The
regression coefficient for the mediator is termed b, and the new regression
coefficient for the predictor in this equation is termed c’.
a

X

M

b

c (c’)

X

Figure 1. Path diagram for the indirect effect of a predictor on a dependent variable
through a mediator.
In order to satisfy the requirements for mediation, c, a, and b must be significant.
Also, the decrease from c to c’ (indirect effect) must be significant as tested by the Sobel
test. The Sobel test divides the value of the indirect effect by its standard error and
compares the result to a standard normal distribution (Sobel, 1982).
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A power analysis using Power and Precision 2.0 (Biostat, 2000) indicated that for
a correlational analysis with a Type I error rate of .05 (two-tailed), the sample size of the
current study (N = 95) would yield power equal to .85 for detecting a medium-sized
effect (r = .30). A second analysis was conducted to determine the power of the
hierarchical multiple linear regression model described above. It indicated that a model in
which Step 1 (i.e., past history of depression) accounts for 10% of the variance in
depressive symptomatology, Step 2 (i.e., demographic and clinical variables) accounts for
an additional 10% of the variance, Step 3 (i.e., psychosocial variables) accounts for an
additional 20% of the variance, power is equal to .82 with a Type I error rate of .05 and
95 participants for detecting a 5% increase in variance accounted for by stigma on Step 4.
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Results

Participants
Eight hundred thirty-nine participants were screened for this study; of these, 680
were ineligible based on medical record reviews (e.g., history of other cancer, not
receiving chemotherapy). The remaining 159 participants were approached for
participation; of these, an additional 17 were deemed ineligible before consent, 33
refused to participate, and 109 agreed to participate (77% of those eligible). Of those who
agreed to participate, 4 withdrew from the study, 4 never completed the study measures
and could not be reached, and 6 were found to be ineligible after they participated. Thus,
analyses were conducted on the 95 participants who had evaluable data, 66 of whom
were living with a spouse/partner and were included in the sub-analyses with dyadic
adjustment (See Figure 2 for a participant flow chart). The 109 patients who agreed to
participate in the study did not differ in terms of age, gender, or race from the 33 patients
who declined to participate, ps ≥ .48.
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Assessed for eligibility
(n= 839)
Ineligible for participation
(n = 680)
Approached for consent
(n = 159)
Ineligible before consent
(n = 17)
Refused to participate
(n = 33)
Consented
(n = 109)
Ineligible after consent
(n = 6)

Withdrew from study
(n = 4)

Failed to complete measures
(n = 4)
Completed study measures
(n = 95)
Living with spouse/partner
(n = 66)

Figure 2. Participant Flow Chart
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Participants ranged in age from 42 to 83 years (M = 64.04; SD = 8.79). The
majority of the participants were high school graduates (60%), married (61.1%), and
White (92.6%). Mean Body Mass Index for this sample was 26.44 (SD = 5.18), which
indicates that the average participant was slightly overweight. On average, participants
were 18.14 months (SD = 30.35) from their original lung cancer diagnosis. Forty-five
(47.4%) participants had surgery for this cancer and 41 (43.2%) had been treated with
radiation therapy. The possible range of scores on the CES-D is from 0 to 60. The range
of scores for this sample was 0 to 44. The mean CES-D score was 14.39 (SD = 8.26), and
38% of participants (n = 36) met the CES-D cutoff for clinically significant depressive
symptoms (≥16). Thirteen participants (13.7%) met criteria for a diagnosis of Past Major
Depressive Disorder, and 16 (16.8%) were taking antidepressant medications at the time
of the study visit. Twelve participants (12.6%) were never smokers, 68 (71.6%) were past
smokers, and 15 (15.8%) were current smokers at the time of the study visit (see Tables 1
and 2 for complete demographic and clinical information). All measures had adequate
internal consistency reliability, (Cronbach’s alphas ≥ .72; see Table 3 for descriptive
statistics and internal consistency reliabilities for each measure).
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Table 1
Demographic Characteristics of the Sample (N = 95)
Variable

M

SD

Age, years

64.04

(8.79)

Pack Yearsa

35.43

(23.70)

Variable

n

%

Gender
Males
Females

39
56

(41.1%)
(58.9%)

Education
≤ High school graduate
> High school graduate

38
57

(40.0%)
(60.0%)

Race
White
Non-White

88
7

(92.6%)
(7.4%)

Ethnicity
Hispanic
Non-Hispanic

3
92

(3.2%)
(96.8%)

Marital Status
Currently Married
Not Married

58
37

(61.1%)
(38.9%)

Total household income
< $ 40,000
≥ $40,000
Declined to answer

22
44
29

(23.2%)
(46.3%)
(30.5%)

Alcohol use in past month
No
Yes

42
53

(44.2%)
(55.8%)

Cigarette use
Never
Previous
Current

12
68
15

(12.6%)
(71.6%)
(15.8%)

a

Among only past smokers and current smokers (n = 83).
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Table 2
Clinical Characteristics of the Sample (N = 95)
Variable

M

SD

Body Mass Index

26.44

(5.18)

Months Since Original Diagnosis

18.14

(30.35)

Variable

n

%

Disease Stage
II
III
IV

3
29
63

(3.2%)
(30.5%)
(66.3%)

ECOG Performance Status
0
1
2–3

20
62
13

(21.0%)
(65.3%)
(13.7%)

Diagnosis of Past Major Depression
No
Yes

82
13

(86.3%)
(13.7%)

Taking antidepressant medication at time of study visit
No
Yes

79
16

(83.2%)
(16.8%)

Had Surgery for This Cancer
No
Yes

50
45

(52.6%)
(47.4%)

Had Radiation Therapy for This Cancer
Never
Before current course of chemo
Currently

54
33
8

(56.9%)
(34.7%)
(8.4%)

Note: ECOG = Eastern Cooperative Oncology Group.
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Table 3
Mean, Standard Deviations, and Internal Consistency Reliabilities of Psychosocial
Scales
Scale

M

SD

α

Social Impact Scale

42.90

11.87

.95

Dyadic Adjustment Scale

16.94

3.55

.83

ENRICHD Social Support Instrument

22.74

3.04

.91

CRI – Cognitive Avoidance

7.85

3.94

.72

Dysfunctional Attitudes Scale

103.62

25.92

.89

CES-D

14.39

8.26

.84

Note: CRI = Coping Responses Inventory; CES-D = Center for Epidemiologic Studies
Depression Scale.

Relationship of Perceived Stigma and Depressive Symptomatology
Correlational analyses were conducted to test the hypothesis that perceived
stigma would be would be positively related to depressive symptomatology (see Table 4).
As hypothesized, these correlations indicate that more social rejection, financial
insecurity, internalized shame, social isolation, and greater overall perceived stigma as a
result of one’s lung cancer diagnosis were significantly related to greater depressive
symptomatology.
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Table 4
Correlations Between Depressive Symptomatology and Perceived Stigma (N = 95)
Variable

Depression (CES-D)

p-value

Perceived Stigma (SIS Total)

.46

< .001

Social Rejection (SocRej)

.29

.004

Financial Insecurity (FinIns)

.43

< .001

Internalized Shame (IntSha)

.27

.010

Social Isolation (SocIso)

.58

< .001

Note: CES-D = Center for Epidemiologic Studies Depression Scale; SIS = Social Impact
Scale.

Relationships of Other Psychosocial Variables with Depressive Symptomatology
A second set of correlational analyses was conducted to test the hypotheses that
poorer social support, poorer dyadic adjustment, more avoidant coping, and more
dysfunctional attitudes would be related to depressive symptomatology (see Table 5). As
hypothesized, these correlations indicate that poorer social support, poorer dyadic
adjustment, more avoidant coping, and more dysfunctional attitudes were significantly
related to greater depressive symptomatology.
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Table 5
Correlations Between Depressive Symptomatology and Psychosocial Variables (N = 95)
Variable

Depression (CES-D)

p-value

Social Support (ESSI)

-.33

.001

Dyadic Adjustment (DAS-4)a

-.48

< .001

Avoidant Coping (CRI CA)

.36

< .001

Dysfunctional Attitudes (DAS)

.48

< .001

Note: CES-D = Center for Epidemiologic Studies Depression Scale; ESSI = ENRICHD
Social Support Instrument; DAS-4 = Dyadic Adjustment Scale – 4; CRI CA = Coping
Responses Inventory Cognitive Avoidance Subscale; DAS = Dysfunctional Attitudes
Scale.
a

Among only those who were living with a spouse or partner (n = 66);

Relationships of Demographic and Clinical Variables with Depressive
Symptomatology
In order to determine if demographic and clinical variables were associated with
depressive symptomatology, t-tests, ANOVAs, and correlational analyses were
conducted (see Tables 6 and 7). No demographic variables were found to be related to
depressive symptomatology (ps > .05). In contrast, two clinical variables were found to
be related to depressive symptomatology. Those with a diagnosis of past Major
Depressive Disorder reported greater depressive symptomatology (M = 19.31; SD =
11.27) than those without a diagnosis of past Major Depressive Disorder (M = 13.60; SD
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= 7.48) (p = .02). Also, patients for whom more time had elapsed since their lung cancer
diagnosis reported greater depressive symptomatology, r(93) = .20, p = .048.
Table 6
Relationships Between Depressive Symptomatology and Demographic Variables (N =
95)
Variable

Depression (CES-D)

p-value

Age (years)

r = .05

.66

Gender (m, f)

t = -1.0

.32

Education (< H.S., ≥ H.S.)

t = -1.26

.21

Race (White, non-White)

t = -1.57

.12

Ethnicity (Hispanic, non-Hispanic)

t = -0.29

.77

Marital Status (married, not married)

t = -0.29

.78

Total Household Income (< $40k, ≥ $40k)

t = 0.71

.48

Alcohol Use in Past Month (yes, no)

t = 0.28

.78

Cigarette Use (never, previous, current)

F = 0.30

.75

r = .01

.92

Pack Years
a

Among only past smokers and current smokers (n = 83).
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Table 7
Relationships Between Depressive Symptomatology and Clinical Variables (N = 95)
Variable

Depression (CES-D)

p-value

t = 2.37

.02

BMI

r = .07

.52

Months Since Original Diagnosis

r = .20

.05

Months Since Recurrencea

r = -.01

.98

Disease Stage (II, III, IV)

F = 0.23

.80

ECOG Performance Status (0, 1, 2-3)

F = 0.71

.50

Surgery (yes, no)

t = -0.40

.69

r = .23

.12

F = 0.98

.38

r = .00

.98

r = -.12

.24

r = .07

.63

t = -0.42

.67

Diagnosis of Past Major Depression (yes, no)

Months Since Surgeryb
Radiation Therapy (never, previous, current)
Months Since Radiation Therapyc
Chemotherapy infusions for this course
Previous chemotherapy coursesd
Antidepressant medication (yes, no)

Note: ECOG = Eastern Cooperative Oncology Group
a

Among only those with a recurrence of Non-Small Cell Lung Cancer (n = 30); bAmong

only those who had surgery; cAmong only those who received radiation therapy (n = 41);
d

Among only those who received a course of chemotherapy previous to the current

course (n = 45).
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Regression Analysis of Depressive Symptomatology
Based on the findings that perceived stigma was related to depressive
symptomatology, a hierarchical regression analysis was conducted to determine if
perceived stigma accounted for significant variability in scores on the CES-D above and
beyond that accounted for by relevant variables (see Table 8). Diagnosis of past Major
Depressive Disorder was specified for inclusion in the model prior to conducting
analyses, time since original lung cancer diagnosis was included in the model because of
its relationship with depressive symptomatology (see Table 7), and psychosocial
variables were included based on the pre-specified model. As shown in Table 8,
diagnosis of past Major Depressive Disorder accounted for 5% of the variance and time
since original lung cancer diagnosis accounted for 4% of the variance in depressive
symptomatology. Social support, avoidant coping, and dysfunctional attitudes were
entered into the equation in the third step. Together, they accounted for an additional 35%
of the variance in depressive symptomatology. Lastly, perceived stigma was entered into
the model in the fourth step. It accounted for an additional 3% of the remaining variance
in depressive symptomatology. As hypothesized, perceived stigma accounted for a
statistically significant amount of additional variance in depressive symptomatology (p =
.043). Together, these variables accounted for 47% of the variance in depressive
symptomatology.
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Table 8
Summary of Hierarchical Regression Analysis for Variables Predicting Depressive
Symtpomatology (CES-D) (N = 95)
Variable

β

Step 1

ΔR2
.05

History of MDD

.25*

Step 2

.04
Time Since Diagnosis

.11

Step 3

.35
Social Support (ESSI)

-.11

Avoidant Coping (CRI CA)

.27**

Dysfunctional Attitudes (DAS)

.33**

Step 4

.03
Perceived Stigma (SIS)

.19*

Note. Overall F (6, 88) = 12.43, p < .001; CES-D = Center for Epidemiologic Studies
Depression Scale; MDD = Major Depressive Disorder; ESSI = ENRICHD Social Support
Instrument; CRI CA = Coping Responses Inventory Cognitive Avoidance Subscale; DAS
= Dysfunctional Attitudes Scale; SIS: Social Impact Scale.
* p < .05, ** p < .01;
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A second hierarchical regression analysis was conducted with a subset of the
sample (n = 66) that was living with a spouse or partner and was eligible to complete the
Dyadic Adjustment Scale – 4 (see Table 9). Diagnosis of past MDD was entered into the
model in the first step and accounted for 8% of the variance in depressive
symptomatology. Time since original lung cancer diagnosis was entered in the second
step and accounted for an additional 5% of the variance. Social support, avoidant coping,
dysfunctional attitudes, and dyadic adjustment were added in the third step and accounted
for an additional 39% of variance. Perceived stigma was added in the fourth step and
accounted for 4% of the remaining variance. As hypothesized, perceived stigma
accounted for a statistically significant amount of additional variance in depressive
symptomatology (p = .028). Together, these variables accounted for 56% of the variance
in depressive symptomatology.
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Table 9
Summary of Hierarchical Regression Analysis for Variables Predicting Depressive
Symtpomatology (CES-D) Among Participants Living With a Spouse or Partner (n = 66)
Variable

β

Step 1

ΔR2
.08

History of MDD

.14*

Step 2

.05
Time Since Diagnosis

.18

Step 3

.39
Social Support (ESSI)

-.15

Avoidant Coping (CRI CA)

.11

Dysfunctional Attitudes (DAS)

.30**

Dyadic Adjustment (DAS-4)

-.11

Step 4

.04
Perceived Stigma (SIS)

.24*

Note. Overall F (7, 58) = 10.42, p < .001; CES-D = Center for Epidemiologic Studies
Depression Scale; MDD = Major Depressive Disorder; ESSI = ENRICHD Social Support
Instrument; CRI CA = Coping Responses Inventory Cognitive Avoidance Subscale; DAS
= Dysfunctional Attitudes Scale; DAS-4 = Dyadic Adjustment Scale – 4; SIS = Social
Impact Scale.
* p < .05, ** p < .01
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Additional hierarchical regression analyses were conducted to determine which
components of perceived stigma contributed unique variance to depressive
symptomatology. The Social Rejection and Internalized Shame subscales did not
contribute significant variance to depressive symptomatology (ps ≥ .49); however, the
Financial Insecurity and Social Isolation subscales did contribute significant variance to
depressive symptomatology (see Tables 10 and 11). Similar trends were found, in
analyses which included the Dyadic Adjustment Scale – 4 among the participants who
were living with a spouse or partner (not shown). These findings suggest that financial
insecurity and social isolation are the components of perceived stigma that may be most
associated with depressive symptomatology.

34

Table 10
Summary of Hierarchical Regression Analysis for Variables Predicting Depressive
Symtpomatology (CES-D) (n = 95)
Variable

β

Step 1

ΔR2
.05

History of MDD

.25**

Step 2

.04
Time Since Diagnosis

.11

Step 3

.35
Social Support (ESSI)

-.11

Avoidant Coping (CRI CA)

.25**

Dysfunctional Attitudes (DAS)

.37**

Step 4

.03
Financial Insecurity (SIS FinIns)

.19*

Note. Overall F (6, 88) = 12.53, p < .001; CES-D = Center for Epidemiologic Studies
Depression Scale; MDD = Major Depressive Disorder; ESSI = ENRICHD Social Support
Instrument; CRI CA = Coping Responses Inventory Cognitive Avoidance Subscale; DAS
= Dysfunctional Attitudes Scale; DAS-4 = Dyadic Adjustment Scale – 4; SIS = Social
Impact Scale.
* p < .05, ** p < .01

35

Table 11
Summary of Hierarchical Regression Analysis for Variables Predicting Depressive
Symtpomatology (CES-D) (n = 95)
Variable

β

Step 1

ΔR2
.05

History of MDD

.22**

Step 2

.04
Time Since Diagnosis

.08

Step 3

.35
Social Support (ESSI)

-.10

Avoidant Coping (CRI CA)

.24**

Dysfunctional Attitudes (DAS)

.27**

Step 4

.07
Social Isolation (SIS SocIso)

.33**

Note. Overall F (6, 88) = 12.53, p < .001; CES-D = Center for Epidemiologic Studies
Depression Scale; MDD = Major Depressive Disorder; ESSI = ENRICHD Social Support
Instrument; CRI CA = Coping Responses Inventory Cognitive Avoidance Subscale; DAS
= Dysfunctional Attitudes Scale; DAS-4 = Dyadic Adjustment Scale – 4; SIS = Social
Impact Scale.
* p < .05, ** p < .01
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Relationships of Demographic and Clinical Variables with Perceived Stigma
In order to determine if demographic and clinical variables were associated with
perceived stigma, t-tests, ANOVAs, and correlational analyses were conducted (see
Tables 12 and 13). Age was associated with perceived stigma, such that younger patients
reported greater perceived stigma. Also, those who reported no alcohol use in the past
month (M = 45.19, SD = 11.30) reported greater perceived stigma than those who
reported using alcohol in the past month (M = 40.00, SD = 12.06). In addition, patients
with a diagnosis of past Major Depressive Disorder (M = 48.91, SD = 12.71) as well as
those with an ECOG performance status of 2 or 3 (M = 50.63, SD = 12.70) reported
greater perceived stigma as compared to those without a history of Major Depressive
Disorder (M = 41.86, SD = 11.48) and those with performance statuses of 0 (M = 40.69,
SD = 10.35) or 1 (M = 41.99, SD = 11.70).
Although no hypotheses were offered, multivariate stepwise analyses were
conducted to determine which of these demographic and clinical variables contributed
significant variance in perceived stigma (see Table 14). Age and performance status were
the only variables that contributed significant variance in perceived stigma above and
beyond that contributed by one another.
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Table 12
Relationships Between Perceived Stigma and Demographic Variables (N = 95)
Variable

Perceived Stigma (SIS)

p-value

Age (years)

r = -.21

.04

Gender (m, f)

t = 1.14

.26

Education (< H.S., ≥ H.S.)

t = -1.01

.32

Race (White, non-White)

t = -1.19

.24

Ethnicity (Hispanic, non-Hispanic)

t = 0.38

.71

Marital Status (married, not married)

t = 0.95

.35

Total Household Income (< $40k, ≥ $40k)

t = 0.68

.50

Alcohol Use in Past Month (yes, no)

t = 2.16

.03

Cigarette Use (never, previous, current)

F = 0.23

.80

r = .18

.08

Pack Years
a

Among only past smokers and current smokers (n = 83).
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Table 13
Relationships Between Perceived Stigma and Clinical Variables (N = 95)
Variable

Perceived Stigma (SIS)

p-value

Diagnosis of Past Major Depression (yes, no)

t = 2.09

.04

BMI

r = -.15

.14

Months Since Original Diagnosis

r = .12

.25

Months Since Recurrencea

r = .02

.91

Disease Stage (II, III, IV)

F = 0.63

.54

ECOG Performance Status (0, 1, 2-3)

F = 3.46

.04

Surgery (yes, no)

t = -0.60

.55

r = .12

.45

F = 0.08

.92

Months Since Radiation Therapyc

r = .05

.74

Chemotherapy infusions for this course

r = .02

.85

Previous chemotherapy coursesd

r = .17

.26

Antidepressant medication (yes, no)

t =1.38

.17

Months Since Surgeryb
Radiation Therapy (never, previous, current)

Note: ECOG = Eastern Cooperative Oncology Group
a

Among only those with a recurrence of Non-Small Cell Lung Cancer (n = 30); bAmong
only those who had surgery; cAmong only those who received radiation therapy (n = 41);
d
Among only those who received a course of chemotherapy previous to the current
course (n = 45).
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Table 14
Summary of Stepwise Regression Analysis for Variables Predicting Perceived Stigma
(SIS) (n = 95)
Variable

β

Step 1

ΔR2
.05

ECOG Performance Status (0, 1, 2-3)

.22*

Step 2

.05
Age

-.22*

Note. Overall F (2, 92) = 4.94, p < .01; SIS = Social Impact Scale; ECOG = Eastern
Cooperative Oncology Group.
* p < .05
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Mediational Analyses
In order to determine which psychosocial variables would be tested for mediation
of the relationship between perceived stigma and depressive symptomatology,
correlational analyses were conducted between perceived stigma and social support,
avoidant coping, dysfunctional attitudes, and dyadic adjustment (see Table 10). Social
support, dysfunctional attitudes, and dyadic adjustment were all significantly correlated
with perceived stigma (ps < .01); avoidant coping was not (p = .45). Thus, three separate
mediational analyses were conducted to determine if social support, dysfunctional
attitudes, or dyadic adjustment mediated the relationship observed between perceived
stigma and depressive symptomatology. The method described by MacKinnon, et al.
(2007) was employed to determine if there is a direct effect (c) between the predictor and
dependent variable which is mediated by the proposed mediator.
Table 15
Correlations Between Perceived Stigma and Psychosocial Variables (N = 95)
Variable

Perceived Stigma (SIS)

p-value

Social Support (ESSI)

-.35

.001

Dyadic Adjustment (DAS-4)a

-.35

.004

Avoidant Coping (CRI CA)

.08

.450

Dysfunctional Attitudes (DAS)

.43

< .001

a

Among only those living with a spouse or partner (n = 66).
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The first model tested whether social support mediated the relationship of
perceived stigma to depressive symptomatology. Perceived stigma was a significant
predictor of depressive symptomatology (B = .32, p < .001) as well as social support (B =
-.09, p < .001). After controlling for social support, there was a reduction in the
regression coefficient for perceived stigma (B = .28, p < .001), indicating that the effect
of perceived stigma on depressive symptomatology was partially mediated by social
support; however, the Sobel test was only marginally significant (z = 1.70, p = .089),
suggesting no mediational relationship (see Figure 3).

B = -.09**

Perceived Stigma
(SIS)

Social Support
(ESSI)

B = .32** (B = .28**)

B = -.53*

Depressive
Symptomatology
(CES-D)

Figure 3. Proposed Model of Social Support (ESSI) as a Mediator Between Perceived
Stigma (SIS) and Depressive Symptomatology (CES-D). ESSI: ENRICHD Social
Support Instrument; SIS: Social Impact Scale; CES-D: Center for Epidemiologic Studies
Depression Scale; Sobel test z = 1.70, p = .089.
*p < .05, **p < .01
The second model tested whether dyadic adjustment mediated the relationship of
perceived stigma to depressive symptomatology. Perceived stigma was a significant
predictor of depressive symptomatology, B = .40, p < .001, as well as dyadic adjustment,
B = -.10, p = .005. After controlling for dyadic adjustment, there was a reduction in the
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regression coefficient for perceived stigma to B = .28, p < .001, indicating that the effect
of perceived stigma on depressive symptomatology was partially mediated by dyadic
adjustment. Sobel’s test was significant (z = 2.10, p = .036), adding further support to the
mediation model (see Figure 4).

B = -.10**

Perceived Stigma
(SIS)

Dyadic
Adjustment
(DAS-4)

B = .40** (B = .32**)

B = -.80**

Depressive
Symptomatology
(CES-D)

Figure 4. Proposed Model of Dyadic Adjustment (DAS-4) as a Mediator Between
Perceived Stigma (SIS) and Depressive Symptomatology (CES-D) aAmong only those
participants who were living with a spouse or partner (n = 66); DAS-4 = Dyadic
Adjustment Scale-4; SIS = Social Impact Scale; CES-D = Center for Epidemiologic
Studies Depression Scale; Sobel test z = 2.10, p = .036.
*p < .05, **p < .01

The third model tested whether dysfunctional attitudes mediated the relationship
of perceived stigma to depressive symptomatology. Perceived stigma was a significant
predictor of depressive symptomatology, B = .32, p < .001, as well as dysfunctional
attitudes, B = .94, p < .001. After controlling for dysfunctional attitudes, there was a
reduction in the regression coefficient for perceived stigma to B = .22, p < .001,
indicating that the effect of perceived stigma on depressive symptomatology was partially
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mediated by dysfunctional attitudes. Sobel’s test was significant (z = 2.82, p = .005),
adding further support to the mediation model (see Figure 5).

B = .94**

Perceived Stigma
(SIS)

Dysfunctional
Attitudes (DAS)

B = .32** (B = .22**)

B = .11**

Depressive
Symptomatology
(CES-D)

Figure 5. Proposed Models of Dysfunctional Attitudes (DAS) as a Mediator Between
Perceived Stigma (SIS) and Depressive Symptomatology (CES-D). DAS = Dysfunctional
Attitudes Scale; SIS = Social Impact Scale; CES-D = Center for Epidemiologic Studies
Depression Scale; Sobel test z = 2.82, p = .005.
*p < .05, **p < .01
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Discussion
Summary of Results
The primary aim of this study was to examine the relationship between perceived
stigma and depressive symptomatology in people with lung cancer. The study also sought
to examine relationships between several psychosocial factors that are related to
depressive symptomatology in other populations and depressive symptomatology in
people with lung cancer. Additionally, it aimed to determine if perceived stigma accounts
for variability in depressive symptomatology in lung cancer patients above and beyond
that explained by psychosocial factors that have been found to be related to depressive
symptomatology in other populations. Lastly, this study sought to determine whether the
psychosocial factors assessed mediated the relationship between perceived stigma and
depressive symptomatology.
Results generally supported the study hypotheses. As expected, greater perceived
stigma was significantly related to higher levels of depressive symptomatology. More
avoidant coping, poorer social support, poorer dyadic adjustment, and more dysfunctional
attitudes were also significantly related to greater depressive symptomatology. Additional
analyses indicated that perceived stigma contributed unique variance in depressive
symptomatology above and beyond that accounted for by clinical (time since lung cancer
diagnosis), demographic (history of past Major Depressive Disorder), and psychosocial
(avoidant coping, social support, dyadic adjustment, and dysfunctional attitudes) factors.
Further analyses showed that financial insecurity and social isolation may be the aspects
of perceived stigma that most contribute to depressive symptomatology. In addition,
younger patients, those who reported no alcohol use in the past month, those with a
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history of Major Depressive Disorder, as well as those with poorer performance statuses
reported greater perceived stigma; however, only age and performance status contributed
significant variance to perceived stigma. Finally, analyses suggested that dyadic
adjustment and dysfunctional attitudes mediated the relationship between perceived
stigma and depressive symptomatology. The following discussion will consider the
theoretical and clinical implications of these findings, describe the study’s limitations,
and identify future research directions suggested by the study findings.
Theoretical and Clinical Implications
As can best be determined, this is the first study to examine the relationship of
perceived stigma to depressive symptomatology in lung cancer patients. This study’s
findings provide quantitative evidence consistent with the qualitative evidence provided
by Chapple and colleagues (2004) which suggested that lung cancer patients experience
significant stigma from others as a result of their illness. Moreover, this study extends
this finding to provide evidence for a link between perceived stigma and depressive
symptomatology as well as possible mediators of this relationship.
Documenting this link among lung cancer patients is important for several
reasons. First, it adds further evidence to the growing body of literature suggesting a
connection between illness-related stigma and depressive symptomatology. As noted
earlier, studies have found that patients with other stigmatizing conditions (e.g., HIV
infection) who report more stigma also report greater depressive symptomatology
(Simbayi, et al., 2007). Second, it adds to knowledge about the possible etiology of
depressive symptomatology among lung cancer patients, a group that is particularly likely
to experience depressive symptoms (Buccheri, 1998; Nakaya et al., 2006).
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This study’s findings are consistent with the Cognitive Theory of Depression,
which states that one’s experiences may contribute to depressive symptomatology by
activating maladaptive schemas, or ways of thinking, from past experiences that are
related to the current situation (Beck & Dempster, 1976; Beck, Rush, Shaw, & Emery,
1979). When activated, these maladaptive schemas begin to perpetuate dysfunctional
attitudes, or faulty reasoning, within the individual that are evident in their automatic
cognitive responses to stimuli. These automatic cognitive responses propagate negative
views of oneself, the experiences one undergoes, and one’s outlook on the future. These
negative thought patterns, the Cognitive Triad, are the most conscious manifestations of
the depressive state and are theorized to result in affective and somatic depressive
symptoms (Beck et al., 1979). This study’s findings suggest that this chain reaction could
be activated in lung cancer patients who perceive they are being stigmatized because of
their illness. Some lung cancer patients may in fact misperceive that they are being
stigmatized because of their illness; however, the effect of misperceived stigma would
likely be similar to that of actual stigmatization. Consider, Beck and colleagues’
explanation of the effects of misperceiving being rejected and socially alienated – two
expressions of stigma:
“For example, if the patient incorrectly thinks he is being rejected, he will react
with the same negative affect (for example, sadness, anger) that occurs with actual
rejection. If he erroneously believes he is a social outcast, he will feel lonely”
(Beck et al., 1979, p. 11).
The finding that those experiencing more stigma also reported greater depressive
symptomatology provides evidence that this process may be under way in some patients
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with lung cancer, an illness for which patients are often stigmatized (Chapple et al.,
2004). Moreover, this study also suggested mechanisms by which stigma may contribute
to depression in lung cancer patients. Specifically, the mediational effect of dysfunctional
attitudes on the relationship between perceived stigma and depressive symptomatology
further suggest that Beck’s Cognitive Theory of Depression may help explain the
etiology of depressive symptoms often experienced by lung cancer patients.
The mediational effects of dyadic adjustment on the relationship between
perceived stigma and depressive symptomatology also suggest additional pathways
through which perceived stigma may lead to or worsen the severity of depressive
symptoms. That is, greater perceived stigma may activate the process which leads to
relational problems with close others which, in turn, might worsen one’s depressive
symptoms. Research in the general population, as well as in chronically-ill populations,
has shown that individuals experiencing poorer dyadic adjustment (Berger et al., 2001;
Miles et al., 1997; Simbayi et al., 2007) report greater depressive symptomatology.
With regard to clinical implications, the findings suggest psychotherapeutic
approaches that might be employed to alleviate or prevent depressive symptoms among
lung cancer patients. Most approaches to reducing stigma are focused on reducing the
stigma that individuals feel towards people of another group (Couture & Penn, 2003).
They are either protests against the injustice of stigmatizing behavior or programs to
educate the public about inaccuracies of stereotypes and replace these inaccuracies with
facts (Corrigan, Kerr, & Knudsen, 2005). These approaches do not seem very applicable
to reducing perceived stigma in lung cancer patients. However, other approaches such as
cognitive therapy may be helpful in counteracting the effects of stigma (e.g.,
48

dysfunctional attitudes) on the stigmatized individual (Corrigan et al., 2005).
Specifically, a modified cognitive therapy approach targeted at altering thoughts and
feelings associated with perceived stigma may prove effective in reducing depressive
symptomatology.
Self-blame is an important component of perceived stigma that warrants attention.
One strategy might involve pointing out to patients that, although it is true that smoking
causes many cases of lung cancer, self-blame is a maladaptive coping strategy after lung
cancer is diagnosed. To help patients move beyond the self-blame they may experience as
a result of perceived stigma, they might be encouraged to present exempting beliefs. For
example, not everyone who smokes gets cancer and not everyone who gets cancer
smoked. Thus, it is impossible to ascertain whether one’s lung cancer diagnosis can be
directly attributable to their smoking. Knowing that one may not necessarily have
“caused” their cancer might help reduce self-blame. The addictiveness of cigarette
smoking and the deception in early tobacco industry advertisements could also be
understood by some patients to put them in the position of having been wronged rather
than being a wrong-doer. Though self-blame can be targeted and reduced, it may remain
in some patients. Those patients should be encouraged to acknowledge the potential for
culpability, then move on to more productive uses of their energies. To help facilitate
this, a psychotherapeutic approach should assist lung cancer patients with helping their
families cope with their illness and its present and future consequences. Patients could
also be offered counseling to aid in their understanding of their illness and their
oncologists’ recommended treatment plan. These and other focuses within the broader
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framework of Cognitive Therapy for depression could help patients move past self-blame
and other consequences of their illness.
Limitations
This study had several limitations. First, the cross-sectional nature of this study
limits the conclusions that can be drawn from its findings. Although the results can be
interpreted as suggesting that stigma contributes to depression, the possibility that
depression contributes to stigma cannot be ruled out. The use of a longitudinal design
would allow the testing of temporal hypotheses. Second, the study’s sample was
relatively homogenous with respect to race and ethnicity, which limits the ability to
generalize to the broader lung cancer patient population. Third, the lung cancer patients
in this study were receiving chemotherapy designed to extend life; thus, this study’s
findings may not generalize to lung cancer patients receiving other types of treatments or
receiving no treatment at all. Lastly, although use of antidepressant medication was not
related to depressive symptomatology in this study, participants’ use of psychotherapy
and related services was not assessed.
Future Directions
Because this is the first quantitative study to identify the relationship between
perceived stigma and depressive symptomatology among lung cancer patients, it will be
important to see if these findings can be replicated in future research. Beyond this, there
is a need for longitudinal research that would allow for examination of the temporal
relationships between perceptions of stigma and depressive symptomatology.
Based on the findings that psychosocial factors mediate the relationship between
perceived stigma and depressive symptomatology, longitudinal study designs should be
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employed in future studies. These designs would enable examinations of temporal
relationships and would allow stronger causal inferences to be drawn. Also, future studies
should examine the potential relationship between the use of psychotherapy services and
depressive symptomatology. Future studies should also aim to recruit samples of lung
cancer patients that are more diverse with regard to race, ethnicity, and socioeconomic
status. Additionally, the use of interventions to reduce depressive symptomatology
among lung cancer patients and other stigmatized groups should consider targeting
stigma and its direct effects.
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